Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
Open Access
- 1 March 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (5), 803-815
- https://doi.org/10.1158/1535-7163.mct-20-0749
Abstract
EWSR1/FLI1, the most common fusion gene in Ewing sarcoma, upregulates expression of the Eyes Absent 3 (EYA3) transactivator–phosphatase protein. The purpose of this study was to investigate molecular and cellular mechanisms through which EYA3 might promote Ewing sarcoma tumor growth and to determine whether the EYA3 tyrosine phosphatase activity represents a viable therapeutic target. We used genetic and pharmacologic modulation of EYA3 in cell line–based xenografts to examine how loss of EYA3 tyrosine phosphatase activity affects tumor growth and angiogenesis. Molecular mechanisms were evaluated in vivo and in vitro through analyses of tumor tissue and multicellular tumor spheroids. Our results show that both loss of EYA3 in Ewing sarcoma cells and pharmacologic inhibition of the EYA3 tyrosine phosphatase activity inhibit tumor growth and tumor angiogenesis. EYA3 regulates levels of VEGFA in Ewing tumors, as well as promoting DNA damage repair and survival of Ewing sarcoma tumor cells. Target engagement is demonstrated in tumor tissue through elevated levels of the EYA3 substrate H2AX-pY142 upon loss of EYA3 or with Benzarone treatment. The efficacy of EYA3 tyrosine phosphatase inhibition in attenuating tumor growth and angiogenesis is corroborated in an Ewing sarcoma patient-derived tumor xenograft. Together, the results presented here validate EYA3 as a target for the development of novel Ewing sarcoma therapeutic strategies, and set the stage for evaluating the efficacy of combining the antiangiogenic and anti-cell survival effects of EYA3 inhibition with cytotoxic chemotherapy.Keywords
Other Versions
Funding Information
- NIH NCI (RO1-CA207068)
This publication has 40 references indexed in Scilit:
- The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by BenzbromaronePLOS ONE, 2012
- A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAsOncogene, 2011
- The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cellsOncogene, 2010
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)Journal of Clinical Oncology, 2009
- Dephosphorylation of the C-terminal Tyrosyl Residue of the DNA Damage-related Histone H2A.X Is Mediated by the Protein Phosphatase Eyes AbsentOnline Journal of Public Health Informatics, 2009
- Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisionsNature, 2009
- WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activityNature, 2008
- A Benefit-Risk Assessment of Benzbromarone in the Treatment of GoutDrug Safety, 2008
- Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteinsProceedings of the National Academy of Sciences of the United States of America, 2007
- Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing’s sarcomaEuropean Journal of Cancer, 2006